Evaluation of efficacy of Sufoof-e-Akseer-e-Jigar in Alcoholic Hepatitis.

Evaluation of Efficacy of Sufoof-e-Akseer-e-Jigar in Alcoholic Hepatitis. - SAJ

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/11/005196

Enrollment

100

Registered

2014-11-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- alcoholic hepatitis

Interventions

Intervention1: Sufoof-e-Akseer-e-Jigar: Age old Standardized Herbal Formulation of Govt. Unani Pharmacopoea, Govt. Indian Medicine Pharmacy Page No. 165 Composition: a)Revand (Rheum emodi) {334 mg}

Eligibility

Inclusion criteria

Inclusion criteria: •Patients clinically diagnosed with Alcoholic Hepatitis. •Patients of both genders with age range between 20-60 years. •Patient should be off from any other therapy for the same ailment 1 week prior to his/her enrollment. •Patients who are willing to give written consent.

Exclusion criteria

Exclusion criteria: •Patients below 20 years and above 60 years. •Pregnant and lactating mothers. •Diabetic patients. •Patient suffering from other systemic diseases. •Patients who does not give written consent.

Design outcomes

Primary

Measure	Time frame
Relief from clinical symptoms and physical signs (Subjective Parameters viz., Anorexia, Nausea, Vomiting,Anxiety,Restlessness, Pain in Abdomen, Low grade Fever, Yellow coloured Urine) along with improvement of biochemical parameters (Objective Parameters viz., Serum Î³-glutamyl transferase, Serum Bilirubin, SGOP, SGPT, Alkaline Phosphotase, Hepatomegaly). An Arbitrary Grading Scale will be adopted for the assessment of subjective parameters. Timepoint: Day 1 Day 15 Day 30 Day 45 Day 60	—

Measure

Time frame

Relief from clinical symptoms and physical signs (Subjective Parameters viz., Anorexia, Nausea, Vomiting,Anxiety,Restlessness, Pain in Abdomen, Low grade Fever, Yellow coloured Urine) along with improvement of biochemical parameters (Objective Parameters viz., Serum Î³-glutamyl transferase, Serum Bilirubin, SGOP, SGPT, Alkaline Phosphotase, Hepatomegaly). An Arbitrary Grading Scale will be adopted for the assessment of subjective parameters. Timepoint: Day 1 Day 15 Day 30 Day 45 Day 60

—

Secondary

Measure	Time frame
Short-Term safety as assessed by change in the safety biochemical parameters (like CBP, ESR, FBS, PPBS, LFT, RFT), and overall compliance to the drug treatment.Timepoint: Day 1 Day 60	—

Countries

India

Contacts

Public ContactDr Ashfaque Ahmed

Govt. Nizamia Tibbi College

principalgntc@gmail.com09394778847

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026